These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28353372)

  • 21. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy.
    Coleman CI; Haas S; Turpie AG; Kuhls S; Hess S; Evers T; Amarenco P; Kirchhof P; Camm AJ;
    Clin Cardiol; 2016 Oct; 39(10):565-569. PubMed ID: 27362695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world persistence with direct oral anticoagulants (DOACs) in naïve patients with non-valvular atrial fibrillation.
    Ferroni E; Gennaro N; Costa G; Fedeli U; Denas G; Pengo V; Corti MC
    Int J Cardiol; 2019 Aug; 288():72-75. PubMed ID: 31043323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life.
    Becattini C; Franco L; Beyer-Westendorf J; Masotti L; Nitti C; Vanni S; Manina G; Cattinelli S; Cappelli R; Sbrojavacca R; Pomero F; Marten S; Agnelli G
    Int J Cardiol; 2017 Jan; 227():261-266. PubMed ID: 27843050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Portuguese Observational Study of Ischaemic Stroke in Patients Medicated with Non-Vitamin K Antagonist Oral Anticoagulants.
    Beato-Coelho J; Marto JP; Alves JN; Marques-Matos C; Calado S; Araújo J; Cunha L; Pinho J; Azevedo E; Viana-Baptista M; Sargento-Freitas J
    Eur Neurol; 2018; 79(1-2):108-112. PubMed ID: 29421803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants.
    Serrao A; Lucani B; Assanto Manfredi G; Fiori L; Baldacci E; Aprile SM; Chistolini A
    J Thromb Thrombolysis; 2020 Oct; 50(3):718-723. PubMed ID: 32112201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of direct oral anticoagulants in patients undergoing cardioversion for atrial fibrillation: A systematic review and meta-analysis of the literature.
    Dentali F; Botto GL; Gianni M; Ambrosino P; Di Minno MN
    Int J Cardiol; 2015 Apr; 185():72-7. PubMed ID: 25791094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation.
    Abrahami D; Renoux C; Yin H; Fournier JP; Azoulay L
    Thromb Haemost; 2020 Oct; 120(10):1384-1394. PubMed ID: 32717756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
    Van Der Meersch H; De Bacquer D; De Vriese AS
    Am Heart J; 2017 Feb; 184():37-46. PubMed ID: 27892885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and effectiveness of oral anticoagulants in patients with atrial fibrillation and stage 4 chronic kidney disease: a real-world experience.
    Talerico R; Brando E; Luzi L; Vedovati MC; Giustozzi M; Verso M; Di Gennaro L; Basso M; Ferretti A; Porfidia A; De Candia E; Pola R; Agnelli G; Becattini C
    Intern Emerg Med; 2024 Sep; 19(6):1645-1652. PubMed ID: 38943034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct oral anticoagulant- vs vitamin K antagonist-related nontraumatic intracerebral hemorrhage.
    Tsivgoulis G; Lioutas VA; Varelas P; Katsanos AH; Goyal N; Mikulik R; Barlinn K; Krogias C; Sharma VK; Vadikolias K; Dardiotis E; Karapanayiotides T; Pappa A; Zompola C; Triantafyllou S; Kargiotis O; Ioakeimidis M; Giannopoulos S; Kerro A; Tsantes A; Mehta C; Jones M; Schroeder C; Norton C; Bonakis A; Chang J; Alexandrov AW; Mitsias P; Alexandrov AV
    Neurology; 2017 Sep; 89(11):1142-1151. PubMed ID: 28814457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study).
    Başaran Ö; Beton O; Doğan V; Tekinalp M; Aykan AÇ; Kalaycıoğlu E; Bolat İ; Taşar O; Şafak Ö; Kalçık M; Yaman M; Altun İ; Soylu MÖ; Kırma C; Biteker M;
    Anatol J Cardiol; 2016 Oct; 16(10):734-741. PubMed ID: 27723665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Satisfaction of Patients with Nonvitamin K Anticoagulants Compared to Vitamin K Antagonists: a Systematic Review and Meta-analysis.
    Katerenchuk V; Duarte GS; Martins E Pereira G; Fernandes RM; Ferreira JJ; Pinto FJ; Costa J; Caldeira D
    Thromb Haemost; 2021 Mar; 121(3):366-382. PubMed ID: 33160289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in oral anticoagulant prescription in patients with nonvalvular atrial fibrillation in Flanders and the impact of switching patients from vitamin K antagonists to DOACS in terms of the burden caused by complications of the disease: a registry-based study.
    Nakhoul E; Vaes B; Mamouris P; Degryse JM
    Acta Clin Belg; 2023 Aug; 78(4):261-269. PubMed ID: 36172878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation.
    Yoshihisa A; Sato Y; Sato T; Suzuki S; Oikawa M; Takeishi Y
    BMC Cardiovasc Disord; 2018 Jan; 18(1):11. PubMed ID: 29368593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.